Physiology · PeptideU · 7 min read

Pegcetacoplan: Physiology and What Research Reports

The short answer

Pegcetacoplan is a pegylated, cyclic peptide that binds complement protein C3 and C3b, blocking the cascade at a central point rather than downstream. It first reached approval for paroxysmal nocturnal haemoglobinuria, and has since been studied by subcutaneous infusion in complement-mediated kidney disease and by intravitreal injection in geographic atrophy. Published trials report changes in haemoglobin, proteinuria and retinal lesion growth, alongside adverse events such as injection-site reactions, breakthrough haemolysis and new exudative macular degeneration.

What Pegcetacoplan Is

Pegcetacoplan is a pegylated peptide therapeutic: two identical cyclic peptides derived from the compstatin family, joined to a large polyethylene glycol (PEG) chain. The peptide portion is what binds the target; the PEG portion slows clearance so the molecule persists long enough to be dosed intermittently rather than continuously. It was described in the drug-development literature as the first complement C3 inhibitor to reach regulatory approval, initially for adults with paroxysmal nocturnal haemoglobinuria (PMID 34342834).

For readers who encounter the term in peptide contexts, pegcetacoplan is a useful reference point for what a peptide becomes when it is engineered into a prescription medicine: a defined sequence, a defined binding partner, a chemical modification for half-life, and a regulatory file built on randomised trials. It is a prescription product, not a research chemical, and this page describes only what published studies reported.

Where It Acts in the Body

The complement system is a set of circulating plasma proteins, largely made in the liver, that tags and destroys microbes and clears damaged cells. Three activation routes — classical, lectin and alternative — all converge on C3. Cleavage of C3 produces C3a and C3b; C3b opsonises surfaces and feeds forward into C5 cleavage and the membrane attack complex.

Because C3 sits at that convergence point, blocking it interrupts both the opsonisation arm (C3b deposition) and the terminal arm (C5-driven lysis). This is the structural difference between pegcetacoplan and C5 inhibitors such as eculizumab, which leave C3b deposition intact. That distinction is the mechanistic reason researchers tested pegcetacoplan in conditions where C3 fragments accumulate on red cells, on kidney basement membranes, or in the retina.

How It Is Studied and Measured

Different diseases call for different readouts and different routes of administration. The table summarises how the published programmes were structured.

Setting	Route in cited studies	Main measured outcome
Paroxysmal nocturnal haemoglobinuria	Subcutaneous infusion	Haemoglobin, transfusion need, haemolysis markers
C3 glomerulopathy / IC-MPGN	Subcutaneous infusion	Proteinuria, kidney function
Geographic atrophy	Intravitreal injection	Atrophic lesion growth, visual function testing

Biomarker work runs alongside the clinical endpoints. One prospective 2025 exploration sampled aqueous humour from treated eyes and reported changes in the ocular proteome, including complement-related proteins, in patients receiving intravitreal pegcetacoplan for geographic atrophy (PMID 41347874).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

What the Literature Reports

Paroxysmal nocturnal haemoglobinuria

The PEGASUS trial randomised patients with persistent anaemia on eculizumab and reported that pegcetacoplan 1080 mg given subcutaneously twice weekly was superior to eculizumab for change in haemoglobin at week 16 (PMID 33730455). The study also reported reduced transfusion requirements in the pegcetacoplan group compared with the eculizumab group (PMID 33730455).

Later work examined downstream consequences of controlling haemolysis. A 2025 analysis of eculizumab-experienced patients with paroxysmal nocturnal haemoglobinuria reported improvement in iron overload measures after transition to pegcetacoplan (PMID 41155315). Not every patient responded durably: a 2025 case report described repeated severe breakthrough haemolysis events on pegcetacoplan and a subsequent switch to the factor B inhibitor iptacopan (PMID 40974609).

Complement-mediated kidney disease

C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis are defined by complement deposition in the glomerulus, which made a C3-level block a logical candidate. A 2025 randomised trial published in the New England Journal of Medicine reported a reduction in proteinuria with pegcetacoplan compared with placebo in patients with C3 glomerulopathy or immune-complex MPGN (PMID 41337715).

Transplant recurrence has also been examined. Researchers reported on the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3 glomerulopathy or primary immune-complex MPGN (PMID 39810766), and a separate 2025 case report described treatment of paediatric C3 glomerulonephritis (PMID 39871447). Case reports describe single patients and cannot establish how often a response occurs.

Geographic atrophy in age-related macular degeneration

Two multicentre, randomised, double-masked, sham-controlled phase 3 trials — OAKS and DERBY — tested intravitreal pegcetacoplan 15 mg given monthly or every other month, and the investigators reported slowing of geographic atrophy lesion growth relative to sham (PMID 37865470). A 24-month analysis reported treatment effects across consensus-defined features of geographic atrophy on imaging (PMID 38722644), and a microperimetry analysis from OAKS reported differences in measured visual function endpoints between treated and sham eyes (PMID 39954920). Lesion growth is an anatomical measure; whether and how it translates into everyday vision remains the central question in this literature.

Adverse Events: What Studies Report

Adverse events differ by route, because the route determines where the drug is concentrated.

Subcutaneous use in PNH. The PEGASUS trial reported injection-site reactions, diarrhoea, breakthrough haemolysis, headache and fatigue among patients receiving pegcetacoplan (PMID 33730455). Breakthrough haemolysis was severe and recurrent enough in one published case to prompt a change of therapy (PMID 40974609).
Infection risk. Inhibiting complement at C3 reduces defences against encapsulated organisms, and the approval literature describes pegcetacoplan as a C3 inhibitor requiring vaccination-related risk management in that context (PMID 34342834).
Intravitreal use in geographic atrophy. The OAKS and DERBY report described an increased occurrence of new exudative (neovascular) age-related macular degeneration in treated eyes compared with sham (PMID 37865470). A 2025 real-world series reported on clinical usage and the observed safety profile of intravitreal pegcetacoplan outside trial conditions (PMID 41262233).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Nothing here describes how any product should be used.

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Why It Matters to Peptide Readers

Pegcetacoplan is frequently cited as a case study in three themes that recur across peptide science. First, peptides can be scaffolded into high-affinity protein binders — the compstatin lineage began as a small cyclic peptide selected for C3 binding. Second, PEGylation solves the half-life problem that otherwise limits peptide drugs to minutes in circulation. Third, the same molecule behaves differently by route: systemic infusion and intravitreal injection produced different benefit-risk profiles across the trials cited above.

Limits of the Evidence

Several caveats apply when reading this literature. Trials in PNH enrolled patients already on a C5 inhibitor, so the comparison was a switch rather than a first treatment (PMID 33730455). Kidney and paediatric reports include small series and single cases (PMID 39871447). In geographic atrophy, the primary endpoint was lesion area rather than patient-reported vision, and functional analyses were secondary or exploratory (PMID 39954920). Longer follow-up and independent real-world data continue to accumulate.

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

References

Frequently asked questions

Is pegcetacoplan actually a peptide?▾

Yes, in the structural sense. It is built from cyclic peptides of the compstatin family joined to a polyethylene glycol chain, which is why it is classed as a pegylated peptide therapeutic. The drug-development literature described it as the first complement C3 inhibitor to reach approval (PMID 34342834). It is a prescription medicine, not a research-use peptide.

What does pegcetacoplan do in the body?▾

It binds complement protein C3 and its fragment C3b, interrupting the cascade at the point where the classical, lectin and alternative pathways converge. Blocking at C3 affects both C3b deposition on cell surfaces and downstream C5 activation, which is the mechanistic rationale described in the approval literature for its use in complement-driven disease (PMID 34342834).

How does it compare with eculizumab in published trials?▾

The PEGASUS trial randomised patients with persistent anaemia on eculizumab and reported that pegcetacoplan 1080 mg subcutaneously twice weekly was superior to eculizumab for change in haemoglobin at week 16, with fewer transfusions reported in the pegcetacoplan group (PMID 33730455). The comparison was a switch from existing therapy rather than first-line treatment.

What adverse events do studies report?▾

With subcutaneous use in paroxysmal nocturnal haemoglobinuria, researchers reported injection-site reactions, diarrhoea, breakthrough haemolysis, headache and fatigue (PMID 33730455). One case report described repeated severe breakthrough haemolysis leading to a switch to iptacopan (PMID 40974609). With intravitreal use, the phase 3 report described increased new exudative macular degeneration in treated eyes (PMID 37865470).

What did the eye trials measure?▾

OAKS and DERBY were randomised, double-masked, sham-controlled phase 3 trials of intravitreal pegcetacoplan 15 mg monthly or every other month, and investigators reported slowed growth of geographic atrophy lesions versus sham (PMID 37865470). A 24-month analysis examined consensus imaging features (PMID 38722644), and a microperimetry analysis assessed visual function endpoints (PMID 39954920).

Has it been studied in kidney disease?▾

Yes. A 2025 randomised trial reported reduced proteinuria versus placebo in C3 glomerulopathy and immune-complex MPGN (PMID 41337715). Separate reports covered kidney transplant recipients with recurrent disease (PMID 39810766) and a paediatric case of C3 glomerulonephritis (PMID 39871447). Case reports describe individual patients and cannot show how often a given response occurs.

Are there biomarker studies beyond clinical endpoints?▾

A 2025 prospective study sampled aqueous humour from eyes treated for geographic atrophy and reported changes in the ocular proteome, including complement-related proteins (PMID 41347874). In haematology, a 2025 analysis of eculizumab-experienced patients reported improvement in iron overload measures after transition to pegcetacoplan (PMID 41155315). This page is educational only and is not medical advice.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free

References

Keep learning

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.